Urothelial carcinoma (bladder + upper tract) · line 1 · Cisplatin + gemcitabine (urothelial neoadj + metastatic)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	aggressive
Linked regimen	`REG-CISPLATIN-GEMCITABINE-UROTHELIAL`

ID	`IND-UROTHELIAL-METASTATIC-1L-PLATINUM-CHEMO-AVELUMAB`
Type	Indication
Status	status not declared
Diseases	`DIS-UROTHELIAL`
Sources	`SRC-EAU-BLADDER-2024` `SRC-NCCN-BLADDER-2025`

Notes

Reserved for EV+pembro-ineligible. Galsky cisplatin-eligibility critical.

Used By

Algorithms

ALGO-UROTHELIAL-METASTATIC-1L - ALGO-UROTHELIAL-METASTATIC-1L